Search

everythinglearnresearchcommunity

for

Search:↓

Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Disrupting the Tsc2 gene in certain cells leads to thicker skin, larger hair, and changes in hair growth signaling, which can be partly reversed with specific treatment.

Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

A new therapy for a skin blistering condition has not been developed yet.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

Tph cells are linked to the severity of systemic lupus erythematosus.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

Anti-CD19 therapy may help treat SLE and NMOSD.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Targeted cancer therapies can cause new side effects, requiring careful monitoring and management to ensure patient safety.

Tislelizumab can cause cutaneous lupus erythematosus.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

The treatment was not recommended due to limited effectiveness and significant side effects.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Tadalafil and Finasteride may help treat aggressive melanoma.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

CD25+ CD4+ Tregs and certain plasma proteins are linked to hair loss.